Maintenance Therapy After Induction in Metastatic Colorectal Cancer

Authored by Chinmay Jani, published on 2026-11-06 04:01:26.0

  1. Unresectable mCRC With Response or Stable Disease After Induction
    Response or stable disease after approximately 4–6 months of first-line systemic therapy. This algorithm focuses on conventional chemotherapy-based induction regimens. Patients receiving first-line checkpoint immunotherapy or BRAF-targeted combinations require regimen-specific continuation strategies.
    • Confirm Treatment Information
      Confirm regimen received, treatment tolerance, and clinical goals.
      • Which Induction Regimen Was Used?
        • FOLFOX or CAPOX Plus Bevacizumab
          • Fluoropyrimidine Plus Bevacizumab Maintenance
            Use 5-FU/LV or capecitabine plus bevacizumab; for example, the CAIRO3 approach.
            • Monitor Response and Toxicity; Reassess at Progression
              Maintain disease control, limit cumulative toxicity, reassess every 8–12 weeks, CEA (carcinoembryonic antigen) monitoring as appropriate and individualize care. Periodic imaging, toxicity monitoring, and reassessment of treatment goals. At progression, evaluate reintroduction of previously effective induction therapy versus second-line treatment according to prior exposure, response, and residual toxicity.
        • FOLFOX Plus Anti-EGFR
          Cetuximab or panitumumab.
          • Fluoropyrimidine Plus Anti-EGFR Maintenance
            Maintenance generally involves infusional 5-FU/leucovorin plus cetuximab or panitumumab. Use 5-FU/LV or capecitabine with continued anti-EGFR therapy; for example, the VALENTINO approach.
            • Monitor Response and Toxicity; Reassess at Progression
              Maintain disease control, limit cumulative toxicity, reassess every 8–12 weeks, CEA (carcinoembryonic antigen) monitoring as appropriate and individualize care. Periodic imaging, toxicity monitoring, and reassessment of treatment goals. At progression, evaluate reintroduction of previously effective induction therapy versus second-line treatment according to prior exposure, response, and residual toxicity.
        • FOLFOXIRI Plus Bevacizumab
          • Fluoropyrimidine Plus Bevacizumab Maintenance
            Use 5-FU/LV or capecitabine plus bevacizumab; de-escalate after about 4 months if responding.
            • Monitor Response and Toxicity; Reassess at Progression
              Maintain disease control, limit cumulative toxicity, reassess every 8–12 weeks, CEA (carcinoembryonic antigen) monitoring as appropriate and individualize care. Periodic imaging, toxicity monitoring, and reassessment of treatment goals. At progression, evaluate reintroduction of previously effective induction therapy versus second-line treatment according to prior exposure, response, and residual toxicity.
        • FOLFIRI-Based Induction
          For example, FOLFIRI plus bevacizumab.
          • Continue FOLFIRI-Based Therapy; Individualize De-escalation
            Continue 5-FU/LV or capecitabine plus bevacizumab, or continue FOLFIRI if preferred and tolerated. The June 2026 ESMO guideline recommends continuing irinotecan-based treatment until progression or unacceptable toxicity, with individualized de-escalation when appropriate.
            • Monitor Response and Toxicity; Reassess at Progression
              Maintain disease control, limit cumulative toxicity, reassess every 8–12 weeks, CEA (carcinoembryonic antigen) monitoring as appropriate and individualize care. Periodic imaging, toxicity monitoring, and reassessment of treatment goals. At progression, evaluate reintroduction of previously effective induction therapy versus second-line treatment according to prior exposure, response, and residual toxicity.
tosprivacy